Lysine acetylation is a prevalent protein posttranslational modification that regulates many cellular processes. Consequently, there has been significant interest in developing small molecules that manipulate the cellular machinery responsible for modulating lysine acetylation. The clinical use of the HDAC inhibitors vorinostat and romidepsin demonstrates the possibility of treating cancers by modifying cellular lysine acetylation. Bromodomains (Box 1; FiguRe 1) are protein modules that bind to acetylated lysine residues (KAc) and, in the terminology of the 'histone code' (Box 2; FiguRe 2), are viewed as 'readers' of the acetylated lysine state. Bromodomaincontaining proteins (BCPs) are found exclusively as part of larger protein scaffolds, many of which are components of transcriptional regulation. Until recently, there had been little interest in developing ligands for bromo domains or investigating them as therapeutic targets. However, rapid progress in the development of small-molecule ligands of the bromodomain and extra C-terminal domain (BET) family of bromodomains has stimulated intense interest in this area and there are now at least four BET bromodomain ligands in clinical trials.
Atherosclerosis: Form of arteriosclerosis, or thickening of the artery walls, which results from accumulation of calcium and fatty materials including cholesterol.
dihydroquinazolinone-based BET bromodomain ligand [17] . Most recently, Zhao et al. reported a fragment-based approach leading to a range of chemically distinct BET bromodomain ligands [18] .
The nature in which bromodomain ligands have been discovered provides a platform to compare the approaches of phenotypic screening and fragment-based ligand discovery. Herein we discuss these two different approaches to ligand discovery and compare the advantages, disadvantages and types of molecules that result in each case. Despite rapid progress in the bromo domain field, the literature in this area Box 1. Bromodomain structure.
Named after the Drosophila gene brahma where they were first identified [49, 50] , bromodomains have emerged as protein modules that bind to e-N-acetylated lysine residues (KAc) [34, 51, 66, 67] . There are 61 human bromodomains found within 46 proteins in the human proteome, with some proteins containing more than one distinct bromodomain [24, 30, 67] . These protein modules comprise approximately 110 amino acids that form a characteristic, antiparallel, four-helix bundle composed of helices aA, aB, aC and aZ [34, 66, 67] . The acetylated lysine residue binds in a pocket that is predominantly hydrophobic, but which contains four structurally conserved water molecules that act as the base of the pocket. There are often two additional conserved water molecules that reside in the loop region between the aA and aZ helices, known as the ZA loop. KAc donates a hydrogen bond from the e-NH to one of the ZA channel water molecules and accepts a hydrogen bond from a conserved asparagine residue, which is replaced by a tyrosine or threonine in some bromodomains [30] . The KAc also forms a water-mediated hydrogen bond to a conserved tyrosine residue within the pocket. Although these hydrogen-bonding interactions are key for KAc recognition, the inherent affinity of KAc for the bromodomain is low. In the case of the histones, affinity comes from binding of the peptide tail at the entrance to the KAc-binding pocket. In the BET bromodomains there is a clear groove in the bromodomain structure that accommodates the histone peptide. This groove includes a hydrophobic pocket, defined by residues W97, P98 and F99 [BRD2(2) numbering], known as the WPF shelf, which has proved important in the binding of synthetic ligands. Other classes of bromodomains do not have a defined WPF shelf region. Despite high overall structural homology between different bromodomains, sequence variation in ZA and BC loop regions contributes to bromodomains displaying selectivity for certain KAc residues located in defined positions in a given histone peptide [30] . x-ray crystal structure of the second bromodomain of BRD2 in complex with KAc (carbon = purple, PDB code 2DVQ) [26] . The bromodomain marks that are not known to be copied along with the DNA or histones during cell division. Arrowsmith et al. define epigenetics as "heritable changes in gene expression or phenotype that are stable between cell divisions, and sometimes between generations, but do not involve changes in the underlying DNA sequence of the organism" [23] . This is the definition that is usually referred to in the context of the work described in this review and encompasses lysine acetylation and its effect on gene transcription. . Modifications occur to both solvent-exposed regions and residues buried within the nucleosome core. Acetyl groups are a common modification to the e-nitrogen atom of lysine residues, and are added, recognized or removed by histone acetyltransferases, bromodomains and histone deacetylases, respectively (shown in green).
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is currently still tractable and hence provides a unique opportunity for discussing the methods in which small-molecule ligands can be discovered, their subsequent value as chemical probes and their role in therapeutic target validation.
progressed to clinical evaluation, were identified using phenotypic screening.
The discovery of I-BET762 using a cell-based ApoA1 luciferase reporter assay ApoA1 upregulation is protective against atherosclerosis progression and results in anti-inflammatory effects. However, lack of an obvious molecular mechanism for modulating ApoA1 levels had previously hindered therapeutic efforts in this area. A phenotypic approach to identify modulators of ApoA1 expression was therefore ideal in this setting. Researchers at GSK employed a 'chemical genetic' approach to identify small molecules that enhanced ApoA1 expression [3, 4] . To observe ApoA1 upregulation, Nicodeme, Chung and co-workers produced a human HepG2 hepatocyte cell line with an ApoA1 luciferase reporter to screen a library of compounds. The phenotypic screen identified a single enantiomer of the benzodiazepine GW841819X (1; FiguRe 5 ) that caused potent induction of the ApoA1 reporter gene with an EC 50 value of 440 nM. This induction was shown to result from a specific effect on the ApoA1 locus, but the molecular target of the compound was unknown. Structure-activity studies were undertaken to optimize the ApoA1 upregulation activity of GW841819X (1). These studies revealed that the benzodiazepine core was essential for activity and a 6-aryl substituent was The classical approach to medicinal chemistry and drug discovery, prevalent until the 1970s and 1980s, depended on the assessment of compound efficacy at producing a certain desired effect in animal models of diseases. Work to understand the mechanism of these drugs led to a comprehensive understanding of receptor pharmacology in many systems, which in turn prompted a more reductionist approach to drug discovery. A move to more biochemical-based assays, focusing on compound selectivity and affinity for a defined protein target, facilitated the use of high-throughput screens to discover lead compounds [82, 83] . The compounds that were developed in this way showed high affinity and exquisite selectivity for a defined protein target, or narrow group of targets. However, this chapter of drug discovery has been characterized by high attrition of drug candidates in Phase II clinical trials, the point at which compounds are tested for their efficacy in treating patients with the disease being targeted [65, 84] . The reasons for this attrition are complex, but highlight the ability of biological systems to effectively compensate for the loss of a certain component. This attrition is partly a function of ineffective target validation and consequently the importance of this component of the drug discovery process has been highlighted.
Phenotypic screening represents, to some extent, a return to the classical method of assessing compounds for their potential to act as drugs. The phenotypic screen will assess the ability of a compound to produce a desired phenotype in cellular, and less frequently animal, models of disease (FiguRe 3) . A simple example of phenotypic screening is measuring the ability of compounds to cause cell death. A more specific example of a phenotypic screen was used in the identification of I-BET762. A cell-based assay was established that monitored the upregulation of Apolipoprotein A1 (ApoA1), which is known to be associated with protection from atherosclerosis and anti-inflammatory effects [4] . The reason that phenotypic screening was a particularly good approach in this case was the lack of a known molecular mechanism for ApoA1 upregulation that could be targeted therapeutically. Therefore a luciferase-based reporter gene assay system was developed (FiguRe 4). In this system, molecules that led to the upregulation of ApoA1 would also cause expression of firefly luciferase, which generates light as a convenient readout of gene expression. Consequently, this system can be used to conduct an unbiased screen for small molecules that affect the expression of the desired gene, in this case ApoA1.
A significant challenge with the phenotypic screening approach to drug development is identifying the mechanism or mechanisms of action used by the hit compound to produce the desired phenotype. Although it is not a regulatory requirement to know the mechanism of drug action for US FDA approval as a drug, elucidating the compound's mechanism of action might well be required to understand the safety profile of the drug [83] . Typically, some form of pull-down experiment or activity-based profiling is employed to determine the protein target or targets of the active compound [65] . In the case of I-BET762, a series of affinity matrices were developed that ultimately identified the BET bromodomains as the target of the active compounds. siRNA experiments were used to demonstrate that knockdown of BRD4 resulted in the same phenotype (upregulation of ApoA1) as evoked by I-BET762 [4] . present in all active benzodiazepine compounds. A range of groups was tolerated in the 4-position and they could be used to modulate the physicochemical and pharmacokinetic (PK) properties of the compounds. The resulting optimized compound, GSK525762A (2; I-BET762), displayed similar potency in the ApoA1 reporter gene assay (EC 50 700 nM), but possessed superior physicochemical and PK properties than 1, making it more suitable for in vivo experiments. Importantly, it was discovered that having the correct stereochemistry at the 4-postion was critical to ApoA1-modulating activity, implying that the benzodiazepines were interacting with defined molecular targets.
In an attempt to elucidate the target of these compounds, a selection of the benzodiazepines, with EC 50 values obtained from the luciferase reporter assay ranging from nM to inactive, were evaluated for their activity on panels of kinases, ion channels, nuclear receptors, GPCRs and other protein classes known to be drug targets. This screen did not identify the target for these compounds, but instead indicated that they
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Human ApoA1 promoter [7] and the Resverlogix compound RVX-208 (6) [5, 6] . IC 50 values for 1 and 2 were determined by a fluorescence resonance energy transfer assay, and for 3 by an amplified luminescent proximity homogeneous assay (AlphaScreen).
Phenotypic screening & fragment-based discovery of small-molecule bromodomain ligands | Review www.future-science.com might exert their cellular activity through a novel class of targets. In order to define the novel target class a chemoproteomics approach was employed. To facilitate this approach, an affinity matrix that incorporated a derivative of I-BET762 (7; FiguRe 7 ) was produced. A control matrix, which incorporated an inactive analog of I-BET762, was also made. Using these matrices, affinity chromatography was conducted using HepG2 cell lysates. A number of proteins were retained on the active affinity matrix but did not bind to the matrix produced using the inactive analog, indicating that they bound selectively to the active compound. In addition, these proteins were competed off the matrix by addition of 1, suggesting that they were the specific protein targets of the active compound. Using LC-MS/MS, these proteins were identified as BRD2, BRD3 and BRD4, three members of the bromodomain-containing BET family of proteins. As these proteins were the main interacting partners detected, the BET family of BCPs seemed to be the molecular targets for the identified compounds.
To ascertain which part of the BET BCPs bound to the benzodiazepine, f lag-tagged cDNA constructs of BRD2, containing the entire sequence, the N-terminal residues (1-473) and the C-terminal residues (473-801) were transfected into HepG2 cells. Affinity chromatography of the lysates afforded only the full length and N-terminal region of BRD2, showing that benzodiazepines bind Since its inception in the late 1990s, fragment-based drug discovery (FBDD) has evolved into a credible alternative approach to high-throughput screening (HTS) for the generation of drug leads [85, 86] . FBDD differs from standard HTS in a number of important ways. Most significantly, the molecules ('fragments'), that are screened are typically smaller than for a standard HTS library and adhere to the 'rule of three' with a relative molecular mass of <300 Da, a calculated log P of ≤3, up to three hydrogen bond acceptors and up to three hydrogen bond donors [87, 88] . The overall FBDD process can be simplified to the following steps: fragment library design of hundreds or thousands of low-molecular-weight compounds; fragment screening using a range of highly sensitive in vitro biophysical techniques, including NMR spectroscopy, x-ray crystallography and fluorescence-based thermal shift assays to detect low affinity hits (0.1-10 mM); fragment elaboration, involving iterative cycles of synthesis, guided by computational docking and bioaffinity measurement [88] . As a result of characteristics of the fragment library, the hit molecules identified by FBDD are small and hence their absolute affinity for the target tends to be low. This fact presents a challenge in the detection of fragment binding, which is why sensitive techniques such as saturation transfer difference NMR-and mass spectrometry-based approaches can be particularly useful in this context. The concept of ligand efficiency is also important as it identifies molecules that make high-quality interactions with the target protein, despite their low affinity [43] . Improved potency and selectivity of final compounds can be achieved by combining interactions observed in multiple fragments that bind to the target in close proximity to each other, building out from an initial fragment to develop further interactions with the target protein or potentially displacing water molecules that are present in the binding site. FBDD has two important advantages over techniques that identify lead compounds of a higher molecular mass. First, a much greater proportion of chemical space can be sampled using a fragment library than with a HTS technique. Second, as the detected fragment hits must make high-quality interactions with the target for binding to be detected at all, the optimized compounds tend to have high ligand efficiency. These advantages have attracted interest in this methodology from both the pharmaceutical industry and academic community alike, with more than ten clinical candidates developed using this strategy [89] . Notably, in 2011 the first fragment-based drug, vemurafenib, was approved for the treatment of metastatic or unresectable melanoma [90] . Figure 6 . Summary of stages in fragment-based drug discovery. Initial small-ligand hits exhibit high-quality interactions, for example, hydrogen bonds to asparagine residues shown left. Expansion of these hits can increase affinity by interacting with further residues or displacing water molecules (yellow hexagon displacing water shown as red sphere), or increase selectivity by interacting with surrounding variable regions (blue triangle) shown right. FiguRe 8A & B) , and this subject has been extensively reviewed elsewhere [4, [19] [20] [21] [22] [23] [24] [25] [26] .
To confirm that the BET inhibition activity exhibited by I-BET762 was responsible for the modulation of ApoA1 levels, siRNA knockdown of BRD4 was carried out. Progressive knockdown of BRD4 induced a gradual and significant upregulation of ApoA1, whereas knockdown of BRD2 and BRD3 had no effect on ApoA1 expression. This suggested that inhibiting the histone-BRD4 interaction in particular is responsible for upregulation of ApoA1. With the structure-activity relationships (SAR) and high affinity of I-BET762 established, an in vitro fluorescence anisotropy displacement assay was developed to allow profiles of 150 compounds from the benzodiazepine 
Key Terms
Affinity matrix: Pull-down assays are a commonly used technique to identify binding partners through attachment of an affinity label.
x-ray crystal structures:
Protein structures can be obtained from refining x-ray diffraction patterns from single crystals. This requires high purity protein and often lengthy trials in crystallization conditions. siRNA: siRNA is used to prevent translation of specific proteins, and can reinforce an understanding of mode of action through replication of resulting phenotype. showing the occupancy of the e-N-acetylated lysine residues (KAc)-binding pocket by 2. The structure is overlaid with an x-ray crystal structure of human BRD2(1) in complex with the diacetylated histone peptide H4 1-15 KAc12 (PDB ID: 2DVQ; carbon = purple [26] ), demonstrating that 2 occupies part of the peptide-binding groove. (B) The 3-methyl-1,2,4-triazole of 2 acts as an effective KAc mimic and forms similar interactions to KAc (carbon = purple). N(2) is positioned to form a water-mediated hydrogen bond to Y113 and N(3) accepts a hydrogen bond from N156. Structures were aligned using the 'cealign' command in PyMOL.
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The discovery of I-BET151
A second chemotype of ApoA1 upregulators was discovered by GSK and developed in parallel to I-BET762. This series of compounds (including 8-10) was based on the isoxazoloquinoline scaffold, and it was rapidly established that the 3,5-dimethylisoxazole motif was essential for activity ( FiguRe 9 ) [27, 28] .
x-ray crystal structures of 10 bound to BRD4 demonstrated that the 3,5-dimethylisoxazole motif resided in the KAc-binding pocket of BRD4 [11, 29] . The nitrogen atom of the isoxazole ring forms a water-mediated hydrogen bond with Y97 [BRD4(1) numbering] and the oxygen atom forms a direct hydrogen bond with the highly conserved N140 residue ( FiguRe 10A ) [30] . The effective occupancy of the WPF shelf region (Box 1) by the 4-aniline group is believed to contribute significantly to binding affinity ( FiguRe 10B ). Additional packing of the methoxy group against side chain I162 was also evident.
Differential scanning fluorimetry (DSF) analysis demonstrated that 10 was selective for the BET bromodomains, with only a small change in thermal shift (ΔT m ) observed for CREBBP, and no change observed for a number of other phylogenetically diverse bromodomains that were tested [11] . Compound 10 displayed broad anti-inflammatory properties, and therapeutic efficacy against clonogenic potential of mixedlineage leukemia-fusion-driven leukemic cell lines was established in vivo in both murine and human models, with abrogation of BRD3/4 binding to chromatin leading to apoptosis. Mirguet et al. have also reported optimization of I-BET151 with the synthesis of a series of napthyridine derivatives, some of which displayed favorable rat PK properties and efficacy in a mouse model of inflammation [29] .
Mitsubishi compounds, (+)-JQ1 & OTX015
Research by Mitsubishi disclosed in two patents published in 2006 [101] and 2009 [102] identified compounds with a very similar chemotype to I-BET762 (2) using a phenotypic screen. It is possible that the similarity in chemotype results from both companies using similar screening files in the phenotypic assays [31] . The inclusion of benzodiazepine-type scaffolds in screening files is common, as these compounds are recognized as 'privileged structures', which have a high propensity to yield biologically active compounds [32] . Molecular modeling using the thienotriazolodiazepine scaffold disclosed by Mitsubishi and the apo-structure of BRD4(1), led to the design of the derivative (+)-JQ1 by Filippakopoulos et al. [7] . The triazolodiazepine moiety is a key feature in the US FDA-approved drugs alprazolam g-aminobutyric acid receptors and are used in the treatment of anxiety neurosis and hypnotic therapy. To reduce the likelihood of the compounds binding to g-aminobutyric acid receptors, a t Bu ester was incorporated at the C6 position, which is known to reduce this activity [33] . DSF and isothermal titration calorimetry showed that (+)-JQ1 was highly selective for the BET bromodomains, displaying K D values of approximately 50 nM and 90 nM for BRD4(1) and BRD4(2), respectively. No binding to the bromodomains of CREBBP or WDR9 was observed. In addition, the enantiomer of the active compound, (−)-JQ1, showed no affinity for a wide range of bromodomains. A peptide displacement-based amplified luminescent proximity homogeneous assay (AlphaScreen), used to measure the ability of (+)-JQ1 to compete with a H4(KAc) 4 peptide for BRD4 binding, gave IC 50 values for (+)-JQ1 of 77 nM and 33 nM for BRD4(1) and BRD4(2), respectively. Co-crystallization of (+)-JQ1 with BRD2(2) and BRD4(1) revealed that the triazoles bound in a very similar fashion to that of I-BET762 and KAc, forming hydrogen bonds to the conserved asparagine residue and the KAc-binding pocket water molecule. (+)-JQ1 also forms similar interactions to I-BET762 with the WPF shelf region of the BET bromodomains.
A fluorescence recovery after photo bleaching assay was used to show that (+)-JQ1 inhibits the interaction of BRD4 with chromatin, and could directly target the BRD4-NUT oncoprotein, responsible for NUT midline carcinoma (NMC), a rare but highly lethal cancer. (+)-JQ1 induced dose-and time-dependent differentiation of NMC cell lines. Furthermore, there was significant reduction in 18 F-fluorodeoxyglucoseuptake when xenograft NMC mice were treated with (+)-JQ1, without toxicity and weight-loss. The mice also showed marked tumor regression and prolonged overall survival after treatment with (+)-JQ1.
OTX015 is thought to be structurally similar to (+)-JQ1 and is based on structures in the Mitsubishi patents. This compound has been in-licensed by Oncoethix from Mitsubishi.
RVX-208
In a similar manner to Nicodeme et al., Bailey and co-workers from Resverlogix used phenotypic screening with a HepG2 cell-based assay to identify compounds that upregulated ApoA1 expression [5] . The quinolinone-based compound RVX-208 (6; FiguRe 5) was identified, which significantly increased ApoA1 mRNA and high-density lipoprotein (HDL) mass in a dosedependent manner. PK and bioavailability assays in cynomolgus monkeys showed that RVX-208 had favorable pharmacological properties including low systemic clearance, a moderate volume The isoxazole of I-BET151 (10) forms similar interactions with the KAc-binding pocket to KAc and acts as an effective KAc mimic [11] . (B) x-ray crystal structure of 10 bound to human BRD4(1) (PDB ID: 3ZYU; carbon = yellow [11] ). The structure is overlaid with the x-ray crystal structure of human BRD4(1) in complex with the diacetylated histone peptide H4 1-12 KAc5KAc8 (PDB ID: 3UVW; carbon = purple [30] ), demonstrating that the isoxazole moiety resides in the KAc-binding pocket, the pyridyl group binds to the WPF shelf and the quinoline nitrogen atom accepts a hydrogen bond from one of the ZA channel water molecules. Structures were aligned using the 'cealign' command in PyMOL.
Phenotypic screening & fragment-based discovery of small-molecule bromodomain ligands | Review 35 S]-cysteine was delivered. This pulse was chased by unlabelled methionine and cysteine. Production of ApoA1 enriched with the [ 35 S]-label was observed at the time of the pulse in RVX-208 treated cells, indicating that RVX-208 is indeed increasing production of ApoA1. The unlabelled chase enabled the extracellular passage of labeled ApoA1 to be monitored over time; after 150 min intracellular labeled ApoA1 was reduced but extracellular labeled ApoA1 was increased, consistent with the belief that cholesterol flux is responsible for the protective role of HDL against atherosclerosis. Furthermore, dosedependent increases in ApoA1 and HDL cholesterol levels in a preclinical model of atherosclerosis (RVX-208-treated male African green monkeys) agreed with the phenotypic screening results in cells. In addition, a combination of 2D-PAGGE, high-performance liquid chromatography, nondenaturing PAGGE and densitometric scanning demonstrated that RVX-208 increased the size of HDL particles, indicating good therapeutic potential for RVX-208. Following the promising results in African green monkeys, and the observation of larger HDL particles, RVX-208 was tested in healthy humans, showing a 10% rise in ApoA1 levels in comparison with placebo. It was only subsequent to the development of this molecule that its mode of action was discovered to be mediated by BET bromodomain inhibition [6, 31] . Since then, there has been some suggestion that RVX-208 is a weak BET bromodomain ligand, but interestingly shows some selectivity for the second bromodomain over the first [31] .
Fragment-based approaches to the discovery of bromodomain ligands
Fragment-based approaches to the development of ligands for the PCAF bromodomain The first structural information on both bromodomains and their ligands was published by Zhou and colleagues during their investigation aimed at the development of new HIV therapeutics [34] . Initial work showed that Tat transcriptional coactivator recruitment requires binding of KAc50 (Tat-K50Ac) to the bromodomain of the coactivator PCAF [35] . Having established the importance of this interaction, efforts then focused on the development of a small-molecule inhibitor of the Tat-KAc50-PCAF interaction leading to disruption of the viral replication pathway [1] . To identify lead compounds, an NMRbased screen of small-molecules selected from the ChemBridge Corporation collection was conducted. Analysis of ligand-induced protein signal changes in 2D
15 N HSQC spectra, with an emphasis placed on compounds that bound the bromodomain near to the KAc pocket, identified an amino nitrophenyl derivative as a starting point for SAR studies. An ELISA assay, in which the ability of ligands to inhibit the interaction of PCAF with a biotinylated Tat-KAc50 peptide, was used to determine the IC 50 values for a set of 24 compounds, of which 11 was the most effective ( FiguRe 11 ) [1, 36, 37] .
An NMR structure of compound 11 bound to the bromodomain of PCAF suggests that the 2-nitro group forms a hydrogen bond with the phenol of Y802 and possibly Y809. The terminal ammonium group interacts electrostatically with the side chain carboxylate of E750. The methyl group of 11 sits in the hydrophobic KAc binding pocket and this interaction is thought to contribute to the affinity of 11 for the PCAF bromodomain.
This work was extended by Wang et al. who synthesized a range of compounds that included those compounds previously reported by Zhou, and some novel additions [37] . These compounds were investigated in two assays. In the first assay C8166 cells were infected with HIV-1 IIIB . The ability of compounds to inhibit the cytopathic effect of the virus was measured by counting the number of syncytium (multinucleated giant cells) and a percentage inhibition of syncytial cell Figure 11 . The PCAF bromodomain ligand 11 reported by Zhou et al. [1, 36] and the cytotoxic compound 12 reported by Zheng, Wang et al. [37] . ELISA: Enzyme-linked immunosorbent assay; LTR: Long terminal repeat.
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Future Med. Chem. (2014) 6(2) formation was quoted. The cytotoxicity of the compounds in C8166 cells was also measured using a tetrazolium dye (MTT) colorimetric assay. Compound 12 showed improved activity over compound 11 in these assays. However, it should be noted that there is no direct evidence that this increase in activity can be attributed to inhibition of the PCAF bromodomain. Indeed, members of a second series of compounds, which had previously been shown by Zhou to be essentially inactive in binding the PCAF bromo domain, were observed to be effective in the syncytial cell formation and MTT assays [1, 37] . Hence caution should be exercised when interpreting these data.
Fragment-based approaches to the development of ligands for the CREBBP bromodomain CREBBP and its paralog, p300, interact with at least 400 protein partners and are key nodes in the mammalian protein−protein interactome [38] . CREBBP possesses both a bromodomain and histone acetyltransferase (HAT) catalytic activity, and hence can be viewed as both a 'reader' and 'writer' of the histone code. Work by Mujtaba et al. demonstrated that the CREBBP bromodomain binds to KAc382 of p53, linking it to the DNA damage repair mechanisms [39] . To develop small molecules that inhibit the p53-CREBBP bromodomain interaction, Sachchidan et al. FiguRe 12 ). Small-molecule inhibition of the CREBBP bromodomain was then measured using an assay in which a chemical ligand competes against binding of a biotinylated p53-AcK382 peptide immobilized to the GST-fusion CREBBP bromodomain, as assessed by western blot. All but one of these 14 compounds showed selectivity for CREBBP over PCAF as determined by weighted chemical shift perturbations. Two of the compounds, MS2126 (13; FiguRe 12 ) and MS7972 (14), were found to almost completely block the CREBBP bromodomain-p53 interaction at 100 µM and 50 µM, respectively. Results from a cell-based study showed that compounds 13 and 14 dramatically decreased p53 expression levels in response to doxorubicin stimulation, validating the CBP-p53 interaction as an interesting therapeutic target.
The same group screened a structurally diverse library of 3000 compounds using an NMR-based assay and identified the azobenzene moiety as a new scaffold for the inhibition of the CREBBP bromodomain [40] . This screen generated ten hits, some of which contained the azobenzene motif, suggesting that compounds containing this moiety were good candidates for optimization. With the aim of improving the potency and selectivity for the CREBBP bromodomain, 26 derivatives of compound 17 (FiguRe 13) were synthesized and evaluated in [40] .
Phenotypic screening & fragment-based discovery of small-molecule bromodomain ligands | Review www.future-science.com a p53-dependent, p21 luciferase reporter gene assay, which measured the ability of each compound to modulate DNA-damage-induced p53 activation in U2OS cells. Each compound had a stronger affinity than the initial hit 17, which gave 4.6% inhibition of p53 activity at 50 µM in U2OS cells. A tryptophan fluorescence-based binding assay was then used to determine the K D for the six compounds that showed >80% inhibition of the interaction between a biotinylated p53-AcK382 peptide and the GST-tagged CREBBP bromodomain. Of these, ischemin (18) exhibited a K D = 19 µM and cellular activity with IC 50 = 5 µM in the luciferase assay. Selectivity of 18 against CREBBP was assessed using the tryptophan fluorescence-based binding assay, which revealed that this compound was up to fivefold selective over the bromodomains of BRD4(1), PCAF, BAZ1B and BAZ2B.
Ischemin (18) was found to completely prevent U2OS cells from undergoing doxorubicininduced cell cycle arrest. Further studies on the effects of 18 on p53 stability and function as a transcription factor revealed its mode of action involves alteration of post-transcriptional modification states on p53 and histones. These results confirmed that upon doxorubicin exposure, ischemin inhibits p53-induced p21 activation by preventing recruitment of CREBBP [40] . RT-PCR array experiments indicated that 18 can reduce doxorubicin-induced expression of p53 target genes. Finally, studies involving primary neonatal rat cardiomyocytes and TUNEL assay measurements indicated that 18 inhibits doxorubicininduced apoptosis, demonstrating that 18 is cellpermeable and functions as a cellular protective agent against myocardial ischemic stress.
Fragment-based discovery of the 3,5-dimethylisoxazole moiety as a KAc mimic The bromodomain ligands described above have been shown to reside predominantly in the peptide-binding groove rather than the bromodomain KAc-binding pocket. However, a number of fragments have now been identified that reside in the KAc-binding pocket and closely mimic the interactions formed by KAc and the bromodomain [12] [13] [14] 17] . Of these fragments, the 3,5-dimethylisoxazole motif has been independently discovered by a number of groups and has emerged as an excellent KAc mimic that can form the basis of ligands for the BET [11, 13, 14, 27, 29, 41] and CREBBP [14, 15] bromodomains.
Development of an AlphaScreen-based peptide displacement assay by Philpott et al. revealed that the solvent N-methylpyrrolidone (19; FiguRe 14) binds to the CREBBP bromodomain in a weak, but ligand-efficient, manner [14, 16, 42, 43] . Screening of a range of N-methylpyrrolidone analogs identified the dihydroquinazolinone (DHQ; 20) core as a promising KAc mimic and the 3,5-dimethylisoxazolecontaining DHQ derivative (21) displayed an unexpectedly low IC 50 value of approximately 7 µM against BRD4(1) in the initial assay [14] .
Although 21 was later shown to inhibit BRD4(1) with an IC 50 value of 4.8 µM, this was not the compound bound in an x-ray crystal structure with BRD4(1). The crystal structure indicated that the DHQ unit was susceptible to oxidation and had conjugated with ethylene glycol from the crystallization buffer (22; FiguRe 15 ), via presumed formation of an iminium ion [14] . Consequently, the dihydroquinazolinone unit was too large to access the KAc-binding pocket and hence the 3,5-dimethylisoxazole was observed to bind in the pocket and act as a KAc mimic. Additionally, the ethylene glycol unit occupied the WPF shelf in BRD4(1) suggesting that this might be a favorable interaction for BET affinity. Initial docking studies indicated that a 3,5-substituted phenyl ring would project substituents into the WPF shelf and the ZA channel. Compound 23, which possesses secondary alcohol and ethoxy substituents showed an IC 50 value of 4.8 µM for BRD4(1) and increased selectivity for the BET bromodomains over CREBBP compared with 22. An x-ray crystal structure of 23 bound to BRD4(1) indicated that the methyl group of the secondary alcohol occupies the WPF shelf while the ethoxy group is oriented into the ZA channel.
Optimization of the methyl group to a phenyl ring improved the interaction with the WPF shelf, giving 24. Removing the ethyl group to give the phenol (25) allowed hydrogen bonding [14] . The 3,5-dimethylisoxazole moiety was independently identified by Bamborough et al. [13] , ultimately leading to the development of a range of potent and selective BET bromodomain ligands. The 3,5-dimethyl-4-phenylisoxazole fragment (27) showed 32% inhibition of BRD3 and 26% inhibition of BRD4 at 200 µM. A comparison of the x-ray crystal structures of the fragment 27 (FiguRe 16), and I-BET762 led to the development of a 3D-pharmacophore model for BET bromodomain binding. A search of commercially available compounds using the pharmacophore gave a number of hits based on the 3,5-dimethylisoxazole with a sulfonamide substituent on the phenyl ring meta to the 3,5-dimethylisoxazole [13] . Both the pharmacophore and docking models indicated that the sulfonamide was effective at directing the attached lipophilic substituent into the WPF shelf. x-ray crystal structures of these ligands bound to BRD2(1) confirmed that the sulfonamide and its substituent were oriented as expected. Initial hits possessed a cyclopropyl ring binding to the WPF shelf (28) but this was optimized to a cyclopentyl ring (29) . A substituent para to the 3,5-dimethylisoxazole was found to be beneficial, with methyl, methoxy and hydroxyl all tolerated. A limitation of the sulfonamide series was their low solubility. This problem was addressed by the incorporation of a morpholine solubilizing group attached to an oxygen atom para to the 3,5-dimethylisoxazole, giving compound 30. This compound has low µM IC 50 values for the BET bromodomains (determined using a time-resolved fluorescence resonance energy transfer assay). DSF ana lysis indicated reasonable selectivity for the BET bromodomains over other BCPs evaluated. Compound 30 showed an IC 50 value of 3.0 µM in a cellular assay based on inhibiting release of IL-6, a cytokine shown to be regulated by BET ligands [3] .
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Hay et al. developed a series of isoxazoles linked to a 5,6-fused ring system targeted at the [14, 16] . The 3,5-dimethylisoxazole motif, indicated in green, occupies the KAc-binding pocket of BRD4 and acts as a KAc mimic. The red substituents occupy the WPF shelf and the blue substituents are oriented into the ZA channel. IC 50 values were determined using an AlphaScreen assay. Ligand efficiency was calculated using the equation (pIC 50 × 1.4 kcal/mol)/heavy atom count [43] . [13] . The green substituent occupies the e-N-acetylated lysine residues-binding pocket and acts as aKAc mimic, the red substituents occupy the WPF shelf. IC 50 values were determined using a time-resolved fluorescence resonance energy transfer assay. FiguRe 17) as a modest BRD4(1) bromodomain with low affinity for the CREBBP bromodomain, whereas compound 33 was more potent but had comparable affinity for both the BRD4(1) and CREBBP bromodomains. Optimization of the indanone core led to the identification of the indanol 32 as a more potent BRD4(1) ligand with some selectivity over the CREBBP bromodomain. The x-ray crystal structure of 32 bound to BRD4(1) shows that the aryl ring occupies the WPF shelf. However, attempts to further optimize this scaffold led to dehydration, forming the corresponding, inactive, indenes.
Optimization of the benzimidazole series first required development of a regioselective synthesis to allow both regioisomers to be obtained separately. These regioisomers result from substitution of one of the two imidazole nitrogen atoms, labeled either g or e for clarity. The g-substituted benzimidazole derivatives were generally more potent against BRD4(1) than the e-substituted compounds.
The 4-cyano-derivative 36 showed an IC 50 value of 200 nM for BRD4(1) and low affinity for the CREBBP bromodomain. Analysis by DSF showed a ΔT m = 3.2°C against BRD4(1) and ΔT m = 1.1°C against the CREBBP bromodomain, with thermal shifts of ≤0.1°C against a panel of phylogenetically diverse bromodomains.
Researchers at Constellation Pharmaceuticals (MA, USA) have recently reported an isoxazole-based BET bromodomain ligand that was developed using hits from a fragment screen [41] . This screen identified several compounds with potencies in the micromolar range. Analysis of co-crystals of these compounds with BRD4(1) led to the selection of 37 (FiguRe 18 ), an analog of 27, as the lead to be progressed, as it mimicked the key interactions formed between BRD4(1) and KAc. Based on the structure of (+)-JQ1 [7] , compound 38 was synthesized, in which the triazole is replaced with the isoxazole ring. This compound FiguRe 19 ), which was identified as a potentially useful bromodomain ligand by a number of groups [12, 14, 42] , formed the basis of work by Fish et al. to develop a BET bromodomain ligand, PFI-1 (43) with a chemotype distinct from other reported compounds. Crystallization of the 6-bromo-DHQ (41) derivative confirmed that the DHQ moiety can act as a KAc mimic and that substitution at the 6-position is tolerated by BRD4(1). Although the bromine atom was a potentially useful synthetic handle via a variety of coupling reactions, this approach would predominantly produce [41] . The green substituent occupies the KAc-binding pocket and acts as a KAc mimic, the red substituent occupies the WPF shelf. IC 50 values were determined using an AlphaScreen assay. [17] . The green substituent occupies the KAc-binding pocket and acts as aKAc mimic, the red substituents occupy the WPF shelf. IC 50 values were determined using an AlphaScreen assay.
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www.future-science.com molecules with a linear relationship between the DHQ core and the substituent. Fish et al. predicted that addition of a tetrahedral component in the substituent would most effectively orient groups into the WPF shelf. The sulfonamide group was selected as the tetrahedral component and two series of compounds were made, one with the sulfur atom attached to the DHQ core, similar to the compounds reported by Bamborough et al. [13] , and the other with the nitrogen atom attached to the core. Evaluation of these compounds revealed that the series in which the nitrogen atom is attached to the DHQ core (42) showed greater affinity for BRD4(1) compared with the alternative series (40). Addition of an ortho-methoxy substituent to the WPF-shelf-occupying aryl group was observed to be favorable from the perspective of BRD4(1) affinity and compound solubility.
An x-ray crystal of 43 bound to BRD4(1) reveals that this compound binds as predicted, with the DHQ core acting as an effective KAc mimic and the sulfonamide group directing the methoxyphenyl ring into the WPF shelf. The sulfonamide NH forms a water-mediated hydrogen bond with the carbonyl group of L92. It is also possible that the oxygen atom of the methoxy group interacts both with this water molecule and the NH of the sulfonamide. However, in both cases, the distance between the oxygen atom and the other atom is observed as over 3 Å in the x-ray crystal structure, and in the case of the NH, the orientation of the atoms looks to be sub-optimal. Analysis of the x-ray crystal structure does indicate that the methoxy group plays an important role in aiding the molecule to adopt a conformation that is favorable for BRD4(1) binding. The x-ray crystal structure shows that, at least in the binding conformation of the molecule, rotation around the aryl-sulfur bond of the sulfonamide will be restricted. Compound 43 shows good selectivity for the BET bromodomains over the bromodomain of CREBBP (surface plasmon resonance K D = 49 µM). DSF ana lysis over a broader panel of phylogenetically diverse bromodomains indicated that 43 is a selective BET bromodomain ligand. Furthermore, 43 showed <50% inhibition against a panel of kinases, GPCRs and ion channels. The cellular activity of 43 was assessed by demonstrating inhibition of production, and was confirmed using a lipopolysaccharide challenge assay in peripheral blood mononuclear cells (EC 50 1.89 µM). Rat studies indicated attractive oral bioavailability and PK properties.
A separate publication has highlighted the value of this probe in cancer research [44] . Exposing sensitive cell lines to PFI-1 resulted in downregulation of aurora B kinase, providing an alternative method to inhibit the action of this oncology target.
2-thiazolidinone
A fragment-based approach employed by Zhao et al. identified the 2-thiazolidinone core as another KAc-mimicking chemotype [18] . Using the ZINC database, 487 fragments were selected using human expertise and parameters including molecular weight, number of rotatable bonds and log P. Docking using the x-ray crystal structure of (+)-JQ1 bound to BRD4(1) was used to select 41 fragments for crystallization trials. These trials provided structures of nine fragments bound to BRD4(1) with several chemotypes identified as KAc mimics, including the 2-thiazolidinone moiety, which was selected for further optimization. Comparison of the binding modes of 44 ( FiguRe 20) with (+)-JQ1 and fragment 27 (3,5-dimethyl-4-phenylisoxazole; FiguRe 16 ) suggested that affinity gains could be made by the addition of meta-and/or parasubstituents on the phenyl ring of 44. These substituents allowed the addition of hydrophobic moieties to effectively occupy the WPF shelf. Thus a range of sulfonamides based on scaffold 44 were synthesized and screened against BRD4(1) using a fluorescence anisotropy assay.
The sulfonamides 45 and 46 had identical affinities (BRD4(1) IC 50 4.1 µM) but comparison of their crystal structures with BRD4(1) revealed distinct binding modes of the sulfonamide substituents. As expected, the thiophenyl ring of 46 occupies the WPF shelf, but the larger benzyl group of 45 sits in the ZA channel. This led to speculation that the sulfonamide group of 45 was an unnecessary component for binding and prompted investigations into whether a 1,3,5-trisubstituted phenyl ring would lead to increased affinities for BRD4(1). These investigations led to the development of 47, which has an IC 50 value of 230 nM for BRD4(1) and is 17-fold more potent than 45 and 46. An x-ray crystal structure of the trisubstituted analog 47 indicated that the sulfonamide directs the thiophene group into the WPF shelf, with the amide group extending into the ZA channel, making extensive hydrogen bonding interactions with residues in this region.
Compound 47 was found to have good metabolic stability profiles, determined by in vitro liver microsome stability and cytochrome P450 enzyme inhibition assays. A range of the 2-thiazolidinones caused growth inhibition of the human colon cancer HT-29 cell line.
Other KAc-mimicking fragments Chung et al. [12] have reported a number of BET bromodomain-binding fragments in addition to those described above. Using knowledge gained from ana lysis of x-ray crystal structures of existing ligands bound to bromodomains, a library of 1376 compounds, including hydrogen bonding functionality and a small alkyl substituent as a KAc mimic, was assembled. This library was screened using a fluorescence anisotropy assay for activity against BRD2, BRD3 and BRD4. Of these compounds, 132 showed >30% displacement of the fluorogenic ligand from at least one of the tandem BET proteins. From the 132 fragments identified, 40 produced x-ray crystal structures in complex with BRD2(1) [12] . Chung et al. reported six of these structures, two of which include fragment chemotypes previously not known to bind to bromodomains.
Three representative fragments (FiguRe 21) were reported which had never been observed bound in crystallized BET-bromodomains, each containing an acetylsubstituent located in the KAc pocket. The tetrahydroquinoline derivative 13 was an attractive starting point for optimization due to its rigidity and a greater number of interactions with the bromodomain than the native KAc side chain. Other than the amide substituent, fragment 13 only engages in lipophilic interactions with the protein. This small molecule showed reproducible inhibition of IL-6 release from lipopolysaccharide-stimulated peripheral blood mononucleated cells, with IC 50 = 14 µM. The similar structural features of 48 and the commonly used drug acetaminophen (49, paracetamol) directed screening of this compound and the results identified it as another small, highly tractable starting point. Although further development of these fragments has not been reported, they represent excellent starting points for further development. The fact that some fragments are also shown to bind the CREBBP bromodomain indicates that these fragments are potentially useful for development of non-BET bromodomain ligands. [18] . The green substituent occupies the KAc-binding pocket and acts as a KAc mimic, red substituents occupy the WPF shelf and blue substituents occupy the ZA channel. IC 50 values were determined using a fluorescence anisotropy assay. Figure 21 . The three fragments reported by Chung et al. that had not previously been crystallized bound to a bromodomain [12] .
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Recently, Vidler et al. demonstrated the value of structure-based virtual screening, which led to the discovery of four novel KAc mimics [45] .
Clinical studies with BET bromodomain ligands The work described above has shown that the BET BCPs, at least, are 'ligandable' targets, that is, potent and selective ligands have been developed for these proteins. The true challenge of determining BCPs as 'druggable', namely, therapeutically relevant targets with sufficiently potent ligands for in vivo efficacy, remains an open question [46] . Several clinical trials that are currently underway will help to address this question and aspects of these trials are outlined below.
RVX-208
Given that bromodomain ligands function through a clinically novel mode of action, defining clinical trials as successful is contingent on establishing measurable end points that relate inhibition of targets to clinical benefits. Although not developed as a BET bromodomain ligand, RVX-208 (6) became the first BET probe in clinical trials. Following promising preclinical results, a small Phase I study in healthy humans was conducted [5] . Translation of the preclinically observed phenotype was seen in a statistically significant increase in ApoA1 and a trend towards increased HDL-C. Following this successful Phase I trial, two Phase II trials (ASSERT and SUSTAIN) were undertaken, with the principle aim of investigating the appropriate dose range, safety and efficacy of RVX-208. ASSERT measured the percentage change in ApoA1 production with 12 weeks of treatment of patients with stable coronary artery disease who were on statin therapy. Three different doses plus placebo were administered over a 12-week period, and although there were modest dose-dependent increases in levels of ApoA1 expression during this time, these increases were not statistically significant. Consequently, a study of 24 weeks was carried out in the SUSTAIN clinical trial [47, 48] .
One problem observed for a large number of patients treated with RVX-208 in the ASSERT trial was reversible elevated levels of transaminases [46] . Although this effect is often experienced with other forms of treatment, the short length and small scale of the study means that adverse hepatic effects cannot be ruled out during long-term treatment. Levels of transaminase were elevated up to three-times the normal upper limit, most frequently in patients treated with the cardiovascular disease therapeutic simvastatin, on high-dose treatment of alternative statins, or who had elevated enzyme levels at baseline [48] . Therefore, the SUSTAIN trial was limited to patients being treated with only atorvastatin or rosuvastatin, two alternatives to simvastatin, for the treatment of cardiovascular disease. Furthermore, the study excluded high doses of these therapeutics and patients with pre-existing elevations in enzyme levels or high baseline HDL-C levels. As well as HDL-C levels, percentage change in ApoA1 and other biomarkers such as triglycerides, abnormal levels of which contribute to cardiovascular disease, were also monitored in this trial. The SUSTAIN trial reached completion in August 2012 but results have yet to be published.
An additional Phase II trial of RVX-208, ASSURE, was carried out to measure the effect of the compound on atherosclerotic plaque burden in patients with coronary artery disease and low HDL-C levels. The aim of this study was primarily to measure percentage change in atheroma volume, but also look at correlations between atheroma composition and other biomarkers. The trial reached completion in June 2013 and Resverlogix announced -0.4% plaque regression, which failed to meet the trial's primary endpoint of a -0.6% change in atheroma volume. However, patients receiving combination therapy of RVX-208 and rosuvastatin displayed a statistically significant reduction in atheroma volume of -1.43%. By contrast, patients receiving combination therapy of RVX-208 and atorvastatin displayed atheroma progression. Two patent applications have been made as a result of RVX-208's synergistic effect in combination with rosuvastatin [201] . Increases in ApoA1 and HDL-C levels implicate BET bromodomain inhibition in the observed clinical efficacy.
Based on data that suggest HDL directly controls glucose metabolism, an additional Phase II trial, announced in November 2012, will investigate the effect of RVX-208 on males with impaired fasting glucose or impaired glucose tolerance [202] . The study will primarily measure postprandial blood glucose levels, but will also investigate changes in insulin secretion levels and insulin sensitivity. clinical trial to determine the dose for treatment of acute leukemia and other hematological malignancies [203] .
CPI-0610
Constellation Pharmaceuticals have recently announced the entry of their novel BET bromodomain ligand CPI-0610 into Phase I clinical trials for patients with aggressive lymphoma [204] .
I-BET762
I-BET762 (2) is currently in Phase I clinical trials for NMC, a rare but lethal form of lung cancer arising from a genetic translocation, with an estimated completion date of December 2014 [205] .
Discussion
Phenotypic screening identified the BET bromodomains as important therapeutic targets Bromodomains were first discovered in 1992 when the Drosophila gene brahma was found to encode for a protein, brm, which contained a motif common to the SNF2, fsh, SPT7, RING3 and CCG1 proteins. This motif, the bromodomain, was thought to mediate protein-protein interactions involved in transcriptional regulation [49, 50] . In 1999, the NMR structure of the PCAF bromodomain was obtained and KAc was identified as the endogenous ligand for bromodomains [34] . These findings led to the idea that the bromodomain was a module involved in targeting proteins to chromatin by binding to KAc on histone proteins [51] . This work provided the foundations for the discovery of the first unnatural bromodomain ligands. Based on the structural studies, NMR screening was used to identify ligands for the PCAF bromodomain that block binding of PCAF to an acetylated lysine residue on the Tat co-activator, a process that is important in HIV transcription and replication [1] . Despite showing a clear effect in vitro, structural ana lysis of these molecules bound to the PCAF bromodomain suggest that they did not directly mimic the KAc interactions with the bromodomain and, perhaps consequently, only showed low micromolar IC 50 values. In addition, although some selectivity data for these compounds are disclosed, it seems unlikely that these lowmolecular-weight molecules only show affinity for their intended target. Despite further work on these molecules being published, they have not been developed for therapeutic application [36] and, although they are pioneering tool compounds, they are not highly attractive drug leads.
It was the development of the BET bromodomain probes I-BET762 and (+)-JQ1 that demonstrated potent small-molecule bromodomain ligands could be identified [3, 7] . Both of these molecules were discovered as bromodomain ligands by phenotypic screening, in the case of I-BET762, to identify upregulators of ApoA1. By using affinity chromatography, GSK were able to identify members of the BET bromodomain family as the main target of I-BET762. Subsequent siRNA studies indicated that inhibition of BRD4 mainly responsible for the phenotype caused by I-BET762, with the binding to BRD2 and BRD3 less important for the biological effect of the compound. Since I-BET762 had proven cellular activity, as a result of being identified in a phenotypic screen, it was quickly entered into SAR optimization studies, leading to a first-in-class molecule. The fact that both I-BET762 and RVX-208 were developed to upregulate ApoA1 levels, and were only subsequently shown to exert their action via BET bromodomain inhibition, indicates that ligands of the BET bromo domains are an effective route to regulate ApoA1 expression.
In some respects, this work is a classic example of how phenotypic screening is a powerful method for identifying compounds with a particular biological activity, without prior knowledge of a molecular target. Phenotypic screening typically identifies compounds that show a strong cellular effect. This effect often arises from favorable polypharmacology, in which multiple synergistic events combine to evoke the observed activity. Although I-BET762 caused a strong phenotype, this arose, not from polypharmacology, but from a single protein target, BRD4, which was revealed to modulate the effects of the I-BET762. Therefore, unusually, this work is an example of a phenotypic screen revealing a single protein that can be targeted to give the desired phenotypic effect. Given their fundamental role in transcription, it is unlikely that the BET bromodomains would have been viewed as viable therapeutic targets prior to the identification of I-BET762 and (+)-JQ1 as potent and selective ligands for these proteins. The elucidation of the BET bromodomains as ligandable entities has catalyzed intense interest in bromodomains more generally as potential therapeutic targets. Indeed, there is much interest in developing ligands for a wide variety of bromodomains, which will in turn, help to reveal the importance of their biology. The target information obtained from phenotypic studies enabled & enhanced fragment-based bromodomain ligand discovery Given that one main protein target, BRD4, was revealed as being pivotal for the activity of the phenotypically discoveredApoA1 regulators, it was tractable to investigate the molecular basis of bromodomain inhibition. This information subsequently allowed structure-based optimization of compound affinity and physical properties. This strategy would have been less appealing had activity at several important targets been required to achieve the observed phenotype. Although the bromodomains exist exclusively as part of more complex proteins, the BET bromodomains, at least, are stable and can be expressed separately from the rest of their parent protein, which is convenient for conducting biophysical assays and obtaining x-ray crystal structures. Efforts to elucidate the mode of ligand binding to the BET bromodomains were assisted by high-resolution x-ray crystal structures of these proteins in both ligand free and ligand-bound forms. Comparison of the protein-ligand interactions of I-BET762 and (+)-JQ1 allowed the key structural elements responsible for their high affinity to be identified. The availability of this information has been fundamental in underpinning the rapid structure-guided progress made in the development of potent and selective BET bromodomain ligands based on known chemotypes. In addition, fragment-based approaches to bromodomain ligands from novel chemotypes can only be carried out with access to robust biophysical assays, including NMR techniques to identify weak-binding ligands and, ideally, structural information on the mode of compound binding. Such fragment screening approaches have resulted in the discovery of a second generation of BET bromodomain ligands based on a number of novel chemotypes. The 3,5-dimethylisoxazole motif, in particular, was identified as an effective KAc mimic. Importantly, in addition to forming the basis for potent BET bromodomain ligands, 3,5-dimethylisoxazole-based compounds were also shown to bind the bromodomain of CREBBP [14] , indicating that some of the KAc mimics that are effective for the BET bromodomains are potentially transferable to other classes of bromodomains.
Partly as a result of the success with obtaining x-ray crystal structures for the BET bromodomains, structural information is now available for over 30 bromodomains from all of the eight phylogenetically different classes [30] . This work provides vital information to guide structurebased development of selective ligands for all of these bromodomains, and it is likely that selective probes for a wide variety of bromo domains will emerge in the near future. One interesting challenge is the development of probes for bromodomains that do not possess the standard features present in most bromodomains. Notably, 13 bromodomains, including ASH1L, PB1 and the SP proteins, do not contain the KAcbinding asparagine residue, which is conserved in the remaining BCPs [30] . It seems likely that screening a small library based on existing KAc mimics that are known have affinity for the 'standard' bromodomain structure will not yield ligand hits for these proteins. Screening of more diverse libraries will be important for generating new lead compounds for these unusual bromodomains.
Rapid progress in the development of BET bromodomain ligands & applicability of the knowledge gained to development of non-BET bromodomain ligands The phenotypic-based programs to identify efficient upregulators of ApoA1 have been long-term commitments for a number of pharmaceutical companies. However, once the BET bromo domains were identified as potential therapeutic targets, progress in the identification and application of potent and selective ligands for these proteins has been unusually quick. There are a number of factors that have contributed to the rapid development of potent and selective BET bromodomain ligands and consideration of these factors might aid the development of similar ligands for other bromodomains. Development of ligands for a given a class of proteins is often driven by their involvement in a therapeutically significant biological pathway. One aspect that was crucial to the rapid development of ligands for BET bromodomains has been the combination of the interest generated by demonstration that phenotypically discovered BET bromodomain ligands can affect inflammation, leukemias and modulate myc levels [24, 52] . The BET bromodomain ligands provide an alternative to developing drugs that target myc. Such compounds have been a long-standing medicinal chemistry target, which has proved difficult to achieve. The availability of the phenotypically discovered tool compounds led to intensive application of these molecules and consequently a large number of high profile publications on the biology of the BET bromodomains. Importantly, the availability of tool compounds allowed investigations by labs in both academia [53] and industry [54] to rapidly conduct and publish investigations on the merits of targeting the BET bromodomains.
Once the BET bromodomains had been identified as therapeutically promising targets, a number of fragment-based discovery programs began. These programs benefited from much of the information discovered in the phenotypic screening projects (vide supra), especially the availability of purified proteins for biophysical and structural work. However, the fragmentbased discovery programs also benefited from the availability of a range of cellular assays that were used to characterize the bromodomain ligands discovered by phenotypic screening. Both the fluorescence recovery after photobleaching assay employed by the SGC [7] , and investigating the viability of MV4;11 acute myeloid leukemia cells, have become standard methods for assessing the cellular activity of BET bromodomain ligands [11, 16, 24, 53, 54] .
The fast pace of BET bromodomain ligand development is perhaps more remarkable given that these compounds are targeting a proteinprotein interaction (PPI). PPIs are often challenging to inhibit selectively, because their interfaces are usually heavily solvent-exposed, cover large areas, and are structurally featureless or poorly defined [55] . Bromodomains are different from many PPIs in some respects, as although they have large, solvent-exposed grooves, in which the histone tail, or other partner protein, binds, the acetylated lysine residue invariably binds in a defined pocket. The defined and well-structured nature of the KAc-binding pocket is similar to an enzyme active site or receptor ligand-binding pocket, and has consequently allowed the design of drug-like small molecules that are able to inhibit the bromodomain-histone interaction. As far as we know, the KAc-binding pocket is well defined for all of the bromodomains, although structural information is only available for approximately 50% of the bromodomains in the human proteome.
To investigate the tractability of developing small-molecule ligands of non-BET bromodomains, Vidler et al. have conducted an ana lysis of the druggability of 33 bromodomain KAcbinding sites, for which structural information is available [56] , using SiteMap and 105 PDB entries. An interesting component of this ana lysis was on the change in predicted druggability of bromodomains when in the apo form compared with when a ligand (either a small molecule or a peptide) is bound. With the exception of CREBBP, the pocket was not found to be more druggable when a ligand was bound. The bromodomains were grouped by common binding site features, providing useful information on developing compounds that are selective for one bromodomain over another. As would be expected, all bromodomains were classed as more druggable than PPIs with less defined binding pockets available for ligand binding. The ana lysis indicated that 13 bromodomains are druggable; this includes the BET family of BCPs. Five additional bromodomains were viewed as being intermediate in their druggability and the remaining bromodomains were classified as being hard to drug [56] . It should be noted that this categorization should really be viewed as a relative comparison between the druggability of bromodomains rather than an absolute measure of how easy it is to develop small-molecule ligands for each bromodomain. Zhang et al. point out that our view of the druggability of a given bromodomain depends to some extent on the bromodomain ligands that are already available [57] . Consequently, our perspective on which bromodomains are druggable might change as new bromodomain ligands are developed. Therefore, the ana lysis by Vidler et al. ranks the bromodomains in order of their likely druggability based on our current knowledge of ligands, but we should also consider the therapeutic potential of all bromodomains when seeking to develop novel bromodomain ligands.
Given the relatively sparse knowledge of biological pathways involving other sub-families of bromodomains -in some cases little is known beyond a genetic prediction of the incorporation of a bromodomain -and associated difficulties in prediction of phenotypic consequence [58] , it seems likely that determining the clinical benefits of targeting a given bromodomain will require deliberate attempts to generate probes for prospective targets to elucidate a phenotypic response. However, the current work in the field suggests that the increased risk in focusing on targets without identified therapeutic potential is mitigated by the rapid success in developing BET bromodomain ligands, coupled with the emerging importance of bromodomains generally in a range of biological processes.
Phenotypic screening & fragment-based discovery of small-molecule bromodomain ligands | Review www.future-science.com ADME & PK properties of BET bromodomain ligands With only a few BET bromodomain ligands in clinical trials it is difficult to draw broad conclusions on the characteristics of these compounds. (+)-JQ1, which was one of the first BET bromodomain probes reported, has relatively high clearance in mouse, and a relatively short half-life, but a moderate volume of distribution [7] . I-BET762 showed favorable PK in mouse, dog and monkey with moderate oral bioavailability, a large volume of distribution in mouse and a long half-life in dog, however, sub-optimal PK data was observed in rat [59] . The related compound reported by Gehling et al. displays a long half-life in dog, low clearance and a moderate volume. However, this compound (39, FiguRe 18 ) also has a comparatively low oral bioavailability in rats [41] . I-BET151 displays low clearance in mouse and rat but high clearance in dog. It also has a good half-life in mouse, rat and dog, and good bioavailability in mouse and rat. RVX-208 displays low clearance but a relatively short half-life and volume of distribution. PFI-1 is the only fragment-based BET bromodomain ligand for which PK and ADME data are available. This compound has moderate clearance, a short-half life and small volume of distribution, and a relatively low oral bioavailability, which is comparable with that of compound 39.
Given the lack of data it is difficult to compare the ADME and PK characteristics of phenotypically discovered BET bromodomain ligands with those of fragment-based BET bromodomain ligands, although the available data are summarized in supplementARy tABles 1 & 2. The phenotypically discovered ligands have better bioavailability than PFI-1, but it is not clear whether this observation will form the basis of a trend. Interestingly the mean ligand efficiency for the two sets of compounds is very similar, although there is a wider variation of values for the fragment-based compounds. Overall these data suggest that the PK and ADME properties of the fragment-based compounds are likely to be at least comparable to those of the phenotypically discovered compounds.
Future perspective
Despite rapid progress in the development of BET bromodomain ligands, the therapeutic potential of these compounds is currently unproven and, like the field of epigenetic medicine generally, this area is in its infancy. Some have likened the intense interest in bromodomains to the initial period of research on kinase ligands, but it remains to be seen whether bromo domain ligands progress to become important therapeutic compounds in the same way as kinase inhibitors have. The clinical trials that are underway will provide some indication of the answers to these questions for the BET bromodomains in the next 12-24 months. As a result of the interest in the BET bromodomains, there are now a number of high-quality ligands for these proteins and hence there is little incentive to start a program of ligand discovery aimed at these bromodomain at this time. One challenge associated with the BET bromodomain ligands that has yet to be addressed is the development of ligands that selectively inhibit one of the BET BCPs over the other family members, or one of the two tandem bromodomains in a given BET BCP (e.g., BRD4(1) over BRD4(2)). Without selective ligands it is not clear whether this level of discrimination is required for therapeutically important compounds, but one can speculate that such ligands might possess enhanced safety profiles over less selective compounds. The longer-term future of bromodomain research will be concerned with ligand discovery for non-BET bromodomains. Although much work in this area is underway, there are currently no publications detailing potent and selective ligands for the non-BET bromodomains. The ana lysis published by Vidler et al. clearly indicates that bromodomain families other than BETs are potentially ligandable and druggable (vide supra) and it is likely that we will see potent and selective non-BET bromodomain ligands disclosed soon.
Given that bromodomains affect transcriptional regulation, they have the potential to be important in a wide variety of indications. This point is illustrated to some extent by the application of (+)-JQ1 as a prototype male contraceptive [61] and the effect of PCAF ligands on HIV infection [1] . supplementARy tABle 3 lists non-oncology indications and therapeutically important pathways that are affected by removal or malfunction of a BCP. This list indicates that there is significant potential for bromodomain ligands to be therapeutically relevant for a wide range of clinical indications. However, it should be noted that although the BCPs are implicated in the diseases or pathways shown, little is known about the specific role played by the bromodomain in these cases. Research to understand this role will be greatly aided by the development of potent and selective small-molecule bromodomain ligands, similar to those compounds developed for the BET bromodomains.
The success in developing small-molecule ligands for the BET bromodomains inspires confidence that it will be possible to repeat this achievement for other bromodomain families. As we have discussed, the availability of structural information proved key to the rapid progress made with the BET bromodomain ligands. x-ray crystal or NMR structures are available for 37 bromodomains with all eight families represented [30] , which will underpin the development of ligands for these bromodomains. Additionally, the availability of stable constructs of these proteins is essential for use in the biophysical assays that are necessary to generate SAR for rational ligand design. Given the knowledge developed in obtaining structures of these proteins, the elucidation of structures for the remaining bromodomains seems a tractable target. Hence, should a therapeutic indication implicate a BCP for which structural information is not available, existing work should facilitate researchers to obtain these data in an expeditious manner.
A key component of the BET bromodomain programs was a clearly defined cellular phenotype, which resulted from the phenotypic discovery of the initial ligands. It will be important to develop such assays to assess the cellular effects of non-BET bromodomain ligands. Poor translation from preclinical to clinical settings has renewed the demand for more complex phenotypic cellular assays, which better represent diseased states. In the case of BET bromodomains, correlation between MYCN amplification and sensitivity to inhibition was identified through integration of genetic ana lysis with chemosensitivity data from a cell-based screen [62] . The apparent plurality of epigenetic recognition, alongside relatively weak binding, ideally calls for in vitro assays involving larger substrates. For instance, reconstituted modified histones can be refolded into octamers for use in nucleosomal arrays to detect multisite binding of epigenetic readers [63] . This would provide an intermediary for fragment-based development to be more closely connected to phenotypic screens.
A significant challenge for those developing bromodomain ligands and epigenetic medicine generally is the transgenerational heritability of epigenetic marks, especially when developing compounds to treat diseases with a better prognosis than terminal cancer. During mammalian development, accurate replication of both the DNA and epigenetic state are required for maintenance of cell fate [64] . Although germline cells are able to erase the epigenetic marks and 'reset' their epigenome at key points, certain marks evade this reprogramming and are instead transmitted to offspring. The marks that are transmitted and the mechanisms by which this occurs is largely unknown [64] . Clearly these fundamental biological questions will have to be answered before we have a full understanding of the safety considerations for medicines that alter the pattern of epigenetic marks.
Conclusion
Bromodomains have emerged as exciting and ligandable protein modules that might become therapeutically important targets. Although early approaches to developing bromodomain ligands were structure-based, it was the identification of potent and selective BET bromodomain ligands in a phenotypic screen for ApoA1 modulation that has ignited intense research in this field. Both phenotypic and rational design approaches have led to the development of potent and selective BET bromodomain ligands. With three BET bromodomain ligands in clinical trials, the potential of these compounds as drugs will soon be revealed. The future of this field will focus on non-BET bromodomain targets and the success in the development of BET bromodomain ligands means that confidence is high that similar ligands will be developed for a diverse range of other bromodomains. The rapid progress in the understanding of bromodomain biology and their emergence as potential therapeutic targets has been underpinned by the development of potent and selective probes or tool compounds. This approach is vital for effective target validation [65] and it seems certain that this approach will play a key role in understanding the biological role of other bromodomains and validating them as therapeutic targets.
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Bromodomains are KAc-binding protein modules
Recognition of KAc mediates protein-protein interactions, notably, but not exclusively, between histones and transcriptional machinery.
Phenotypic screening identified BET bromodomains as important therapeutic targets
In combination with chemoproteomics, phenotypic screening identified small molecules that modulate ApoA1 levels. These compounds are effective at reversing the effects of leukemias, atherosclerosis and inflammation in preclinical models.
The compounds identified as upregulators of ApoA1 worked by inhibiting the BET bromodomains, revealing BET bromodomain-containing proteins as novel therapeutic targets. Target information enhanced fragment-based approaches to ligand discovery Obtaining x-ray crystal structures of these ligands bound to the BET bromodomains has underpinned subsequent fragment-based ligand discovery programs for bromodomain ligands.
Therapeutic potential of targeting bromodomains
Clinical trials are underway on four BET bromodomain ligands. These studies will give the first indications of whether the powerful tool ligands that have been developed for the BET bromodomains will translate into useful drugs.
This work has stimulated interest in non-BET bromodomains as therapeutic targets with the potential for addressing a wide range of diseases.
The development of selective bromodomain ligands as molecular probes is an important strategy for understanding the biology and therapeutic potential of bromodomain-containing proteins.
Development of a novel chemotype of BET bromodomain probe, from a screen of fragment-sized potential KAc mimics. Structure-activity relationships draw out the importance of subtle variations in connectivity, through an alternative arrangement of a sulfonamide linkage yielding an increase in affinity.
A useful introduction to bromodomains, containing a thorough ana lysis of the protein family: structure-based sequence alignments used to generate a phylogenetic tree, crystal structures across several defined sub-families, and affinities to a panel of modified histone peptide sequences.
